

SYSTEMS BIOLOGY ANALYSIS OF CYTOKINE SIGNALING IN INFLAMMATORY BOWEL DISEASE HIGHLIGHTS THE IMPORTANCE OF TYK2-DEPENDENT PATHWAYS

Vinayagam Arunachalam

UEG Week Berlin 2025

Presentation

Colorectal

Digestive Oncology

IBD

Mechanisms & Personalised Medicine

October 6, 2025

Transcriptomic analysis of 4059 IBD biopsy samples reveals that TYK2-dependent pathways including type I interferon, IL-23, and IL-12 are enriched in UC and CD, remain incompletely addressed by current biologics, and are associated with treatment non-response.

KEY POINTS

- Seven TYK2-dependent gene signature modules (two type I interferon, three IL-23, two IL-12) were defined and analyzed across 4059 biopsy samples from 2993 patients in 15 UC and 38 CD studies.
- Type I interferon signatures were strongly enriched in both UC and CD; IL-23 enrichment was stronger in UC than CD; IL-12 enrichment was stronger in CD than UC.
- All three TYK2-dependent signature enrichments were associated with greater disease severity.
- Treatment with golimumab, infliximab, ustekinumab, or vedolizumab significantly reduced but did not completely ameliorate specific type I interferon and IL-12 modules.
- Enrichment of type I interferon, IL-23, and IL-12 signature modules was associated with non-response to golimumab, infliximab, and vedolizumab.
- The authors conclude that all three TYK2-dependent signalling pathways should be considered in the development of future IBD treatment options.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/9e6dcc4a-a815-11f0-9abe-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.